Business Context and Reporting Period
This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp) on October 9, 2020. The report details the entry into a new material definitive agreement for an equity offering and the termination of a prior sales agreement.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed is the potential capital raise:
- Maximum Offering Size: Up to $7.5 million in aggregate gross proceeds.
- Minimum Sale Price: Shares may not be sold for less than $6.75 per share.
- Placement Fee: 3% of the gross sales price paid to the sales agent.
Material Changes
The Company entered into an At-The-Market Offering Agreement with H.C. Wainwright & Co., LLC, replacing a previous arrangement. Concurrently, the Company terminated its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., which had been in effect since August 21, 2018. The termination of the Cantor agreement became effective on September 13, 2020.
Guidance, Outlook, and Risks
Management has not provided specific financial guidance or outlook in this filing. The Company explicitly states that it is not obligated to sell any shares under the new agreement, and the agent is not obligated to buy or sell any shares. There is no assurance that any shares will be sold, nor regarding the price, amount, or timing of potential sales. The offering is subject to market conditions and customary parameters.
Investor Verification Checklist
- Verify the current trading price of EKSO common stock relative to the $6.75 minimum sale price floor.
- Review the attached Exhibit 1.1 (Offering Agreement) for specific termination rights and conditions.
- Confirm the status of the Form S-3 registration statement (File No. 333-239203) referenced in the filing.
- Monitor future filings for actual sales activity under the new At-The-Market program.